OPKO Health, Inc. Deferred Tax Assets, Unrealized Losses on Available-for-Sale Securities, Gross
OPKO Health, Inc. (OPK) had Deferred Tax Assets, Unrealized Losses on Available-for-Sale Securities, Gross of $1.49 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsUnrealizedLossesOnAvailableforSaleSecuritiesGross · last filed 2026-02-26
- 2025-12-31: Deferred Tax Assets, Unrealized Losses on Available-for-Sale Securities, Gross $1.49M.
- 2024-12-31: Deferred Tax Assets, Unrealized Losses on Available-for-Sale Securities, Gross $2.62M.
- 2023-12-31: Deferred Tax Assets, Unrealized Losses on Available-for-Sale Securities, Gross $2.64M.
- 2022-12-31: Deferred Tax Assets, Unrealized Losses on Available-for-Sale Securities, Gross $2.65M.
| Period end | Deferred Tax Assets, Unrealized Losses on Available-for-Sale Securities, Gross |
|---|---|
| 2025-12-31 | $1.49M 10-K · filed 2026-02-26 |
| 2024-12-31 | $2.62M 10-K · filed 2026-02-26 |
| 2023-12-31 | $2.64M 10-K · filed 2025-03-03 |
| 2022-12-31 | $2.65M 10-K · filed 2024-03-01 |
| 2021-12-31 | $2.58M 10-K · filed 2023-02-27 |
| 2020-12-31 | $2.47M 10-K · filed 2022-03-01 |
| 2019-12-31 | $2.48M 10-K · filed 2021-02-18 |
| 2018-12-31 | $2.45M 10-K · filed 2020-03-02 |
| 2017-12-31 | $2.41M 8-K · filed 2019-01-29 |
| 2016-12-31 | $4.79M 8-K · filed 2019-01-29 |
| 2015-12-31 | $0.00 10-K · filed 2017-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |